Publications by authors named "Daniel Sherbenou"

Claim this Profile
L
Longitudinal profiling of tumor and immune compartments uncovers patterns of dysregulation and associations with response in multiple myeloma.
Denis J Ohlstrom, William C Pilcher, Marina E Michaud, Chaitanya Acharya, Sarthak Satpathy, Daniel W Sherbenou

Blood Cancer Discov· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Ribosome Profiling Reveals Translational Reprogramming via mTOR Activation in Omacetaxine-Resistant Multiple Myeloma.
Zachary J Walker, Katherine F Vaeth, Amber Baldwin, Denis J Ohlstrom, Lauren T Reiman, Daniel W Sherbenou

Mol Cancer Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025.
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, Larry D Anderson, Muhamed Baljevic, Daniel Sherbenou

J Natl Compr Canc Netw· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia.
Mohd Minhajuddin, Amanda Winters, Haobin Ye, Shanshan Pei, Brett Stevens, Daniel W Sherbenou

Haematologica· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-Cell RNA Sequencing before and after Light Chain Escape Reveals Intrapatient Multiple Myeloma Subpopulations with Divergent Osteolytic Gene Expression.
Denis Ohlstrom, Zachary J Walker, Abhishek Pandey, Lorraine N Davis, Krysta L Engel, Daniel W Sherbenou

Cancer Res Commun· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance.
Lorraine N Davis, Zachary J Walker, Lauren T Reiman, Sarah E Parzych, Brett M Stevens, Daniel W Sherbenou

Clin Cancer Res· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ex Vivo Efficacy of SAR442257 Anti-CD38 Trispecific T-cell Engager in Multiple Myeloma Relapsed After Daratumumab and BCMA-targeted Therapies.
Alana L Keller, Lauren T Reiman, Olivia Perez de Acha, Sarah E Parzych, Peter A Forsberg, Daniel W Sherbenou

Cancer Res Commun· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD38 x ICAM-1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphoma.
Xiaocheng Chen, Oi Kwan Wong, Lauren Reiman, Daniel W Sherbenou, Leonard Post

Mol Cancer Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, Larry D Anderson, Muhamed Baljevic, Daniel Sherbenou

J Natl Compr Canc Netw· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology.
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, Larry D Anderson, Muhamed Baljevic, Daniel Sherbenou

J Natl Compr Canc Netw· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD38 antibody re-treatment in daratumumab-refractory multiple myeloma after time on other therapies.
Olivia Perez de Acha, Lauren Reiman, David S Jayabalan, Zachary J Walker, Grace Bosma, Daniel W Sherbenou

Blood Adv· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD46-ADC Reduces the Engraftment of Multiple Myeloma Patient-Derived Xenografts.
Michael J VanWyngarden, Zachary J Walker, Yang Su, Olivia Perez de Acha, Brett M Stevens, Daniel W Sherbenou

Cancers (Basel)· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide-induced autoimmune enteropathy complicating treatment of multiple myeloma with concurrent systemic mastocytosis.
Stephanie Lakritz, Peter A Forsberg, Daniel W Sherbenou, Tomer M Mark

Clin Case Rep· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm.
Alana L Keller, Daniel W Sherbenou, Peter A Forsberg, Tomer M Mark

Front Oncol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sustained Response to Selinexor-Based Therapy for Triple-Class Refractory Multiple Myeloma with Early Relapse After Allogeneic Stem Cell Transplantation.
Daniel Sherbenou, Margaret Stalker, Peter Forsberg, Tomer Martin Mark

Clin Lymphoma Myeloma Leuk· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma.
Lorraine N Davis, Daniel W Sherbenou

Cancers (Basel)· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy.
Zachary J Walker, Beau M Idler, Lorraine N Davis, Brett M Stevens, Michael J VanWyngarden, Daniel W Sherbenou

Clin Cancer Res· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma.
Daniel W Sherbenou, Yang Su, Christopher R Behrens, Blake T Aftab, Olivia Perez de Acha

Clin Cancer Res· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adult cord blood transplant results in comparable overall survival and improved GRFS vs matched related transplant.
Prashant Sharma, Enkhtsetseg Purev, Bradley Haverkos, Daniel A Pollyea, Evan Cherry, Daniel Sherbenou

Blood Adv· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression.
Zachary J Walker, Michael J VanWyngarden, Brett M Stevens, Diana Abbott, Andrew Hammes, Daniel W Sherbenou

Blood Adv· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Maria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, Albert Oriol, David Simpson, Daniel Sherbenou

Lancet Haematol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cellular proliferation by multiplex immunohistochemistry identifies aggressive disease behavior in relapsed multiple myeloma.
Peter A Forsberg, Andrew Hammes, Diana Abbott, Daniel W Sherbenou, Adriana Rossi

Leuk Lymphoma· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disruption of IRE1α through its kinase domain attenuates multiple myeloma.
Jonathan M Harnoss, Adrien Le Thomas, Anna Shemorry, Scot A Marsters, David A Lawrence, Daniel W Sherbenou

Proc Natl Acad Sci U S A· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma.
Peter A Forsberg, Adriana C Rossi, Angelique Boyer, Linda Tegnestam, Roger N Pearse, Daniel W Sherbenou

Am J Hematol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer.
Yang Su, Yue Liu, Christopher R Behrens, Scott Bidlingmaier, Nam-Kyung Lee, Daniel W Sherbenou

JCI Insight· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis